IN 008
Alternative Names: IN-008Latest Information Update: 20 Nov 2023
At a glance
- Originator Inhalon Biopharma
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parainfluenza virus infections
Most Recent Events
- 20 Nov 2023 Discontinued for Parainfluenza virus infections in USA (Parenteral) (Inhalon Biopharma pipeline, November 2023)
- 26 Sep 2023 Inhalon Biopharma has patent protection for muco-trapping technology in USA, Europe and throughout the world (Inhalon Biopharma website, September 2023)
- 26 Sep 2023 Early research in Parainfluenza virus infections in USA (unspecified route) prior to September 2023 ((Inhalon Biopharma pipeline, September 2023)